CeriBell, Inc (CBLL)vsEdwards Lifesciences Corp (EW)
CBLL
CeriBell, Inc
$27.22
0.00%
HEALTHCARE · Cap: $997.83M
EW
Edwards Lifesciences Corp
$91.78
+1.06%
HEALTHCARE · Cap: $49.92B
Smart Verdict
WallStSmart Research — data-driven comparison
Edwards Lifesciences Corp generates 6287% more annual revenue ($6.51B vs $101.96M). EW leads profitability with a 15.4% profit margin vs -64.7%. EW earns a higher WallStSmart Score of 55/100 (C).
CBLL
Avoid28
out of 100
Grade: F
EW
Buy55
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for CBLL.
Margin of Safety
+68.5%
Fair Value
$251.45
Current Price
$91.78
$159.67 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.5% year-over-year
Conservative balance sheet, low leverage
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Strong operational efficiency at 29.8%
Areas to Watch
Trading at 8.1x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Weak financial health signals
Premium valuation, high expectations priced in
Earnings declined 25.4%
Comparative Analysis Report
WallStSmart ResearchBull Case : CBLL
The strongest argument for CBLL centers on Revenue Growth, Debt/Equity. Revenue growth of 32.5% demonstrates continued momentum.
Bull Case : EW
The strongest argument for EW centers on Debt/Equity, Altman Z-Score, Operating Margin. Profitability is solid with margins at 15.4% and operating margin at 29.8%. Revenue growth of 13.6% demonstrates continued momentum.
Bear Case : CBLL
The primary concerns for CBLL are Price/Book, EPS Growth, Market Cap.
Bear Case : EW
The primary concerns for EW are PEG Ratio, Piotroski F-Score, P/E Ratio. A P/E of 51.5x leaves little room for execution misses.
Key Dynamics to Monitor
CBLL profiles as a hypergrowth stock while EW is a mature play — different risk/reward profiles.
CBLL carries more volatility with a beta of 0.93 — expect wider price swings.
CBLL is growing revenue faster at 32.5% — sustainability is the question.
EW generates stronger free cash flow (585M), providing more financial flexibility.
Bottom Line
EW scores higher overall (55/100 vs 28/100), backed by strong 15.4% margins and 13.6% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CeriBell, Inc
HEALTHCARE · MEDICAL DEVICES · USA
CeriBell, Inc. develops AI based point-of-care electroencephalography (EEG) technology for the detection and treatment of neurological conditions. The company is headquartered in Sunnyvale, California.
Edwards Lifesciences Corp
HEALTHCARE · MEDICAL DEVICES · USA
Edwards Lifesciences is an American medical technology company headquartered in Irvine, California, specializing in artificial heart valves and hemodynamic monitoring.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?